Cardiol Therapeutics (CRDL)
Develops oral and injectable therapies for inflammatory heart disease.
Something off on this page? Send us feedback.
Develops anti-inflammatory and anti-fibrotic therapies for heart disease, led by oral candidate CardiolRx. The clinical-stage business also advances CRD-38, an injectable candidate for inflammatory heart disease including heart failure.
Develops anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is an orally administered small molecule in development for recurrent pericarditis. CRD-38 is a subcutaneously administered candidate for inflammatory heart disease, including heart failure.
Clinical execution centers on the Phase III MAVERIC trial for CardiolRx and Phase II ARCHER data. Management remains led by co-founder David Elsley, and the company has a small employee and consultant base in Oakville, Ontario, Canada. The program set remains focused on inflammatory cardiovascular disease rather than a diversified marketed-drug portfolio. Progress depends on clinical, regulatory, intellectual-property, and financing execution.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 26, 2026 | B. Riley | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.5M · Total debt $75.9K · Total assets $20.8M · Shareholders' equity $17.0M
- Revenue
- $0
- Operating income
- −$8.0M
- Net income
- −$6.1M
Reported in CAD, converted at the latest exchange rate
No dividends on record.
| Institutions | 25.61% | 29.52M shares | |
|---|---|---|---|
| 55 holders · as of Jun 30, 2026 | |||
| Other | 74.39% | 85.76M shares | |
| remainder | |||
115.27M company shares as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mmcap International Inc. SPCInstitution | 13.53% | 15.60M | as of Jun 30, 2026 |
Tejara Capital LtdInstitution | 4.44% | 5.11M | as of Jun 30, 2026 |
Ikarian Capital, LLCInstitution | 2.88% | 3.33M | as of Jun 30, 2026 |
Boothbay Fund Management, LLCInstitution | 0.85% | 975,721 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 0.69% | 796,529 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Kiniksa Pharmaceuticals
Approved and pipeline IL-1 therapies for recurrent pericarditis
- Novartis (ADR)
IL-1β biologic explored for recurrent pericarditis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cardiol Therapeutics | $1.84 | −2.91% | $217.9M | — | — | — | — |
| Kiniksa Pharmaceuticals | $75.16 | −3.64% | $5.94B | 79.6 | 46.8 | 7.1 | +55.4% |
| Novartis (ADR) | $142.32 | +0.74% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Median | 50.5 | 31.0 | 5.9 | +28.1% |